TSBX Turnstone Biologics
- 2.450
- +0.080+3.38%
Turnstone Biologics News
Piper Sandler Keeps Their Buy Rating on Turnstone Biologics Corp. (TSBX)
Piper Sandler Maintains Turnstone Biologics(TSBX.US) With Buy Rating, Maintains Target Price $20
Piper Sandler analyst Joseph Catanzaro maintains $Turnstone Biologics(TSBX.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate of 3
Piper Sandler Sticks to Its Buy Rating for Turnstone Biologics Corp. (TSBX)
12 Health Care Stocks Moving In Monday's After-Market Session
GainersLarimar Therapeutics (NASDAQ:LRMR) stock increased by 23.6% to $8.99 during Monday's after-market session. The company's market cap stands at $573.5 million. GT Biopharma (NASDAQ:GTBP) stock ro
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersScorpius Holdings (AMEX:SCPX) shares rose 20.9% to $0.12 during Thursday's after-market session. The market value of their outstanding shares is at $4.3 million. Kintara Therapeutics (NASDAQ:KT
Leerink Partners Reaffirms Their Hold Rating on Turnstone Biologics Corp. (TSBX)
Turnstone Biologics | 10-Q: Quarterly report
Express News | Turnstone Biologics: Expects Combined Cash, Cash Equivalents and Short-Term Investments Will Be Sufficient to Fund Its Operations Into Q3 2025
Express News | Turnstone Biologics Q1 EPS USD -0.85
Express News | Turnstone Biologics Q1 Net Income USD -19.629 Million
Express News | Turnstone Biologics Q1 Operating Expenses USD 20.691 Million
Express News | Turnstone Biologics Q1 Pretax Profit USD -19.613 Million
Express News | Turnstone Biologics Q1 Income From Operations USD -20.691 Million
Express News | Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
Turnstone Biologics to Present at the 2024 Bank of America Securities Health Care Conference
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to tr
Express News | Turnstone Biologics Appoints William Waddill to Its Board of Directors
Turnstone Biologics GAAP EPS of -$0.73 Beats by $0.25
Express News | Turnstone Biologics Q4 EPS $(0.73) Beats $(0.86) Estimate
Turnstone Biologics: Lead Program, TIDAL-01, Advancing in Phase 1 Trials With Initial Clinical Data Expected in Mid-2024 >TSBX
Turnstone Biologics: Lead Program, TIDAL-01, Advancing in Phase 1 Trials With Initial Clinical Data Expected in Mid-2024 >TSBX
Turnstone Biologics 4Q Loss/Shr 73c >TSBX
Turnstone Biologics 4Q Loss/Shr 73c >TSBX
Analysis
Price Target
No Data
